Comparative Pharmacology
Head-to-head clinical analysis: ALMOTRIPTAN MALATE versus TOSYMRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALMOTRIPTAN MALATE versus TOSYMRA.
ALMOTRIPTAN MALATE vs TOSYMRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT1B/1D receptor agonist; cranial vasoconstriction and inhibition of trigeminal nerve transmission.
Sumatriptan is a selective agonist of serotonin (5-HT1B/1D) receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission.
12.5 mg orally at onset of migraine; may repeat after 2 hours if headache recurs. Maximum 25 mg/day.
10 mg intranasally as a single dose, may repeat once after 24 hours if needed. Maximum 2 doses in 7 days.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours. In patients with hepatic impairment, half-life may be prolonged (up to 6-7 hours), necessitating dose adjustment.
Terminal elimination half-life approximately 2.5 hours; clinically relevant for dosing every 4-6 hours.
Approximately 70% renal excretion (40% unchanged, 30% as metabolites), 30% fecal/biliary elimination.
Renal excretion of unchanged drug and metabolites; 70% recovered in urine as parent and metabolites, 30% in feces.
Category C
Category C
Antimigraine Agent
Antimigraine Agent